Science Corp reports a 29-letter average vision gain at 36 months with its PRIMA retinal implant
Image: Science Corporation / newsroom · press-kit
Science Corporation presented 36-month PRIMAvera results on 5 October 2026: patients with geographic atrophy gained 29 letters of visual acuity on average.
Science Corporation presented 36-month results from PRIMAvera, the European trial of its PRIMA retinal implant, at the EURETINA congress in Vienna, announced on 5 October 2026. The implant is a wireless photovoltaic chip placed under the retina of people who have lost central vision to geographic atrophy, an advanced form of age-related macular degeneration.
Thirty-eight patients were implanted at 17 sites in five countries; 18 were evaluable for efficacy at 36 months. Their mean improvement was 29 letters, nearly six lines on an eye chart, up from 24.5 letters at 12 months, and 14 of the 18 gained at least 15 letters. The company reports no new safety signal between months 12 and 36.
These are company-reported conference results, with fewer than half the patients evaluable for efficacy, and no peer-reviewed paper on the 36-month data yet. PRIMA is sold in Europe and the United Kingdom and awaits a decision from the U.S. FDA.
Sources
- Science Corporation Primary source
